澳门太阳游戏城app官网入口

资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized， Multicenter Trial.

Clin Ther. 2018-09; 
LawitzEric，BidairMohamed，MarburyThomas，JonesChristopher T，BarveAvantika，MagnussonBaldur，BarkanDavid T，BodendorfUrsula，BrackenKathryn，CaninoErica，ChenDarlene，DabovicKristina，HeimbachTycho，IsonMarjorie，JonesCatherine L，KovacsSteven J，LakshmanJay P，LiBin，RamanPrakash，Steiner-SwiatRachael，ThohanSanjeev，WongKelly A，ZhongWeidong，ColvinRicha
Products/Services Used Details Operation
Gene Synthesis … 1b replicon. Individual NS3-4A mutations were introduced into GT-1a or GT-1b replicons by gene synthesis (Genscript, Piscataway, New Jersey) and then tested as above. Results. Patient Demographic Characteristics. A total … Get A Quote

摘要

Infection with hepatitis C virus is the leading cause of infectious disease mortality in the United States. BZF961 is a novel small molecule inhibitor of the hepatitis C virus NS3-4A protease. Here we present the results of a randomized， double-blinded， placebo-controlled， multicentered study in treatment-naïve patients with chronic hepatitis C virus genotype-1 infection.

关键词

clinical trial，hepatitis C，protease inhib
Article Link >